Alzheimer’s drugs ‘make no meaningful difference to patients,’ major review suggests
Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK
Alzheimer's Drugs Benefits Questioned
- These new Alzheimer’s drugs could transform treatment The i Paper —
- Newsletter Exclusive: How to reduce your brain's biological age in just three months, by a world-leading neurologist whose regime is clinically proven to work. Use our interactive brain calculator - and follow the guide Daily Mail —
- Dementia drugs hailed as 'beginning of the end' for Alzheimer's do not work, major report finds Daily Mail —
- Alzheimer's drugs make 'no meaningful difference' RTE —
- 'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests BBC News —